Thermo Fisher Scientific completes $1.85B Peprotech acquisition

Thermo Fisher Scientific (NYSE:TMO) announced today that it completed its acquisition of PeproTech for approximately $1.85 billion.

Cranbury, New Jersey-based PeproTech develops recombinant proteins, including cytokines and growth factors, for use in the development and manufacturing of cell and gene therapies, as well as in other broader cell culture applications.

Get the full story at our sister site, Drug Discovery & Development.

Read more
  • 0